Add Company
Join Now

BlueSphere Bio Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • BlueSphere Bio's estimated annual revenue is currently $8.4M per year.(i)
  • BlueSphere Bio's estimated revenue per employee is $155,000

Employee Data

  • BlueSphere Bio has 54 Employees.(i)
  • BlueSphere Bio grew their employee count by -11% last year.

BlueSphere Bio's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Executive Assistant To CEOReveal Email/Phone
3
Co-FounderReveal Email/Phone
4
Co-Founder & SVP Research & DevelopmentReveal Email/Phone
5
FounderReveal Email/Phone
6
SVP, Head Business Development & StrategyReveal Email/Phone
7
VP FinanceReveal Email/Phone
8
VP Product DevelopmentReveal Email/Phone
9
VP, Human ResourcesReveal Email/Phone
10
VP FinanceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.4M9-10%N/AN/A
#2
$7.1M4677%N/AN/A
#3
$14.4M9327%N/AN/A
#4
$0.9M60%N/AN/A
#5
$1.6M1043%N/AN/A
#6
$11.5M746%N/AN/A
#7
$0.9M1122%N/AN/A
#8
$3.7M24-8%N/AN/A
#9
$2M1318%N/AN/A
#10
$9.3M602%N/AN/A
Add Company

What Is BlueSphere Bio?

BlueSphere Bio was founded to unlock the potential of personalized T cell therapy for the treatment of cancer by harnessing the unique specificity of each patient’s own T cells for the particular molecular fingerprint of each patient’s own cancer through our novel TCXpress technology. Our proprietary TCXpress platform is an elegant, rapid approach that exploits the patient’s own immune defenses to attack their cancer specifically, and is designed to leave normal tissues untouched, thereby reducing harmful side effects. The platform and implementation allows us to deliver rapid, personalized T cell treatments for a variety of cancer indications.

keywords:N/A

N/A

Total Funding

54

Number of Employees

$8.4M

Revenue (est)

-11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$13.1M5417%N/A
#2
$15M5493%N/A
#3
$13.1M546%N/A
#4
$15.1M54-18%N/A
#5
$7.5M548%N/A